Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™,
DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV
viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be
effective in maintaining virologic suppression at 48 weeks of treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Stanford University
Collaborators:
Janssen Scientific Affairs, LLC University of Colorado, Denver